Positive News SentimentPositive NewsNASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free CMRX Stock Alerts $0.89 +0.01 (+1.14%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9150-Day Range$0.88▼$1.0552-Week Range$0.88▼$1.42Volume393,188 shsAverage Volume340,809 shsMarket Capitalization$79.78 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Chimerix alerts: Email Address Chimerix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside854.9% Upside$8.50 Price TargetShort InterestBearish1.61% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.99 out of 5 starsMedical Sector195th out of 913 stocksPharmaceutical Preparations Industry82nd out of 429 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has received no research coverage in the past 90 days.Read more about Chimerix's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.61% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Chimerix has recently increased by 0.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 3.8 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Chimerix this week, compared to 1 article on an average week.Search Interest6 people have searched for CMRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have not sold or bought any company stock.Percentage Held by Insiders13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chimerix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.85) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chimerix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Chimerix Stock (NASDAQ:CMRX)Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More CMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Stock News HeadlinesJune 9, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Upgraded to "Hold" by StockNews.comMay 30, 2024 | globenewswire.comChimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceMay 24, 2024 | barrons.comChimerix Inc.May 3, 2024 | markets.businessinsider.comBuy Rating Justified by Chimerix’s Upcoming Catalysts and Strong FinancialsMay 2, 2024 | markets.businessinsider.comStrong Buy Rating for Chimerix on Robust Financials and Promising Drug PipelineMay 2, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comChimerix’s Strong Financials and Promising ONC201 Developments Merit Buy RatingMay 2, 2024 | finance.yahoo.comChimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 2, 2024 | au.finance.yahoo.comQ1 2024 Chimerix Inc Earnings CallMay 1, 2024 | msn.comChimerix GAAP EPS of -$0.25May 1, 2024 | sfgate.comChimerix: Q1 Earnings SnapshotMay 1, 2024 | globenewswire.comChimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateApril 30, 2024 | markets.businessinsider.comWhat Wall Street expects from Chimerix's earningsApril 24, 2024 | globenewswire.comChimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024April 16, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 15, 2024 | finance.yahoo.comWe Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth CarefullyMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 2.000 callMarch 16, 2024 | finance.yahoo.comCMRX Apr 2024 1.000 putMarch 5, 2024 | finance.yahoo.comChimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 2, 2024 | seekingalpha.comChimerix, Inc. (CMRX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comChimerix: Tackling A Strong Unmet Need With Promising DataMarch 1, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Chimerix Amid Progress in Dordaviprone’s Phase III Study and Strong Financial OutlookFebruary 29, 2024 | finanznachrichten.deChimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateFebruary 29, 2024 | finance.yahoo.comChimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees72Year Founded2000Price Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+854.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net Margins-25,337.96% Pretax Margin-201,443.91% Return on Equity-41.32% Return on Assets-37.83% Debt Debt-to-Equity RatioN/A Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$320,000.00 Price / Sales249.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.41Miscellaneous Outstanding Shares89,630,000Free Float77,888,000Market Cap$79.81 million OptionableOptionable Beta1.28 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael T. Andriole M.B.A. (Age 51)CEO, President & Director Comp: $820kDr. Roy W. Ware MBAPh.D., Chief Manufacturing Technology OfficerKey CompetitorsVerastemNASDAQ:VSTMFortress BiotechNASDAQ:FBIOscPharmaceuticalsNASDAQ:SCPHChiasmaNASDAQ:CHMAAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCBought 291,981 shares on 5/10/2024Ownership: 2.426%Koshinski Asset Management Inc.Bought 40,000 shares on 5/9/2024Ownership: 0.045%Marquette Asset Management LLCBought 22,709 shares on 5/7/2024Ownership: 0.129%Assenagon Asset Management S.A.Sold 44,923 shares on 4/24/2024Ownership: 0.509%Michael T AndrioleSold 1,744 sharesTotal: $1,813.76 ($1.04/share)View All Insider TransactionsView All Institutional Transactions CMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price target for 2024? 2 equities research analysts have issued 12 month price targets for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 854.9% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2024? Chimerix's stock was trading at $0.9625 at the start of the year. Since then, CMRX shares have decreased by 7.5% and is now trading at $0.8901. View the best growth stocks for 2024 here. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CMRX earnings forecast. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) announced its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 41.32%. During the same period in the prior year, the firm posted ($0.24) EPS. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). Who are Chimerix's major shareholders? Chimerix's stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.43%), Assenagon Asset Management S.A. (0.51%), Marquette Asset Management LLC (0.13%), Koshinski Asset Management Inc. (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.